<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672980</url>
  </required_header>
  <id_info>
    <org_study_id>RTX-321-01</org_study_id>
    <nct_id>NCT04672980</nct_id>
  </id_info>
  <brief_title>RTX-321 Monotherapy in Patients With HPV 16+ Tumors</brief_title>
  <official_title>A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rubius Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rubius Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321&#xD;
      for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or&#xD;
      metastatic, unresectable, HPV 16+ cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open label, multicenter, multidose, first-in-human (FIH) dose escalation&#xD;
      and expansion to determine the safety and tolerability, recommended phase 2 dose and&#xD;
      pharmacology, and antitumor activity of RTX-321 in adult patients with persistent, recurrent,&#xD;
      or metastatic, unresectable cervical cancer (squamous, adeno, or adenosquamous histology),&#xD;
      HNSCC, or squamous cell cancer of the anal canal that is not amenable to curative therapy.&#xD;
      Prior to study screening, all patients must be confirmed to be HLA-A*02:01 positive.&#xD;
      Documentation of an HPV 16+ tumor is required at prescreening for patients with cervical&#xD;
      cancer and HNSCC. RTX-321 is a cellular therapy that expresses 4-1BBL, IL-12, and HPV-16&#xD;
      Antigen with the goal of harnessing the innate and adaptive immune systems for the treatment&#xD;
      of cancer. The study will include a monotherapy dose escalation phase followed by an&#xD;
      expansion phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment by rate of Adverse Events:</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Measured by incidence of Treatment Emergent Adverse Events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) of RTX-321:</measure>
    <time_frame>up to 30 months</time_frame>
    <description>As determined by incidence and severity of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of RTX-321:</measure>
    <time_frame>up to 30 months</time_frame>
    <description>As measured by the changes in number of CD8+ T-cells in peripheral blood using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of RTX-321:</measure>
    <time_frame>up to 30 months</time_frame>
    <description>As measured by the detection of the number of RTX-321 cells using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of RTX-321</measure>
    <time_frame>up to 30 months</time_frame>
    <description>measured by duration of response (DoR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of RTX-321</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Measured by overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of RTX-321</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Measured by progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of RTX-321</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Measured by overall response rate (ORR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>RTX-321 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RTX-321 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTX-321</intervention_name>
    <description>RTX-321 monotherapy</description>
    <arm_group_label>RTX-321 Dose Escalation</arm_group_label>
    <arm_group_label>RTX-321 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent obtained prior to study procedures Patients ≥18 years&#xD;
             with an ECOG 0 or 1&#xD;
&#xD;
          -  Histologically confirmed diagnosis by the local laboratory of persistent, recurrent,&#xD;
             or metastatic, unresectable cervical cancer (squamous, adeno, or adenosquamous&#xD;
             histology), HNSCC, or squamous cell cancer of the anal canal that is not amenable to&#xD;
             curative therapy.&#xD;
&#xD;
          -  All patients must have experienced disease progression following platinum-based or&#xD;
             mitomycin C-based chemotherapy administered in the persistent, recurrent, or&#xD;
             metastatic setting.&#xD;
&#xD;
          -  All patients with programmed death-ligand 1 (PD-L1) positive cervical cancer and those&#xD;
             with HNSCC must have received or have been determined to be ineligible for&#xD;
             immunotherapy with a PD-1 or PD-L1 inhibitor.&#xD;
&#xD;
          -  All patients with cervical cancer will have received or have been determined to be&#xD;
             ineligible for bevacizumab.&#xD;
&#xD;
          -  Confirmation of HLA-A*02:01 positive status by central testing.&#xD;
&#xD;
          -  In patients with cervical cancer or HNSCC, confirmation of HPV 16 within the tumor&#xD;
             either from historical pathology result (using an FDA-approved HPV testing method,&#xD;
             patients with cervical cancer only) or based on central laboratory analysis of a tumor&#xD;
             sample. Patients with anal cancer will not be required to have prospective&#xD;
             determination of HPV 16 positive status prior to enrollment.&#xD;
&#xD;
          -  Disease must be measurable per Response Evaluation Criteria&#xD;
&#xD;
          -  The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior&#xD;
             therapy, before initiation of study treatment.&#xD;
&#xD;
          -  Adequate Organ Function as Defined by the protocol:&#xD;
&#xD;
               -  AST and ALT ≤3 × the upper limit of normal (ULN)&#xD;
&#xD;
               -  Except in documented cases of Gilbert syndrome, total bilirubin ≤1.5 × ULN&#xD;
&#xD;
               -  Serum albumin ≥2.5 g/dL&#xD;
&#xD;
               -  Serum or plasma creatinine ≤1.5 × ULN and/or glomerular filtration rate ≥50&#xD;
                  mL/min/1.73 calculated by the Cockcroft-Gault formula&#xD;
&#xD;
               -  Absolute neutrophil count ≥1 × 103/μL, without myeloid growth factor support for&#xD;
                  ≥1 week&#xD;
&#xD;
               -  Platelet count ≥100 × 103/μL, without platelet transfusion for ≥1 week&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL, without red blood cell transfusion for ≥2 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has central nervous system (CNS) involvement. If the patient fulfills the&#xD;
             following 3 criteria, she/he is eligible for the trial after consultation with the&#xD;
             Sponsor Medical Monitor.&#xD;
&#xD;
               -  Completed prior therapy for CNS metastases (radiation and/or surgery)&#xD;
&#xD;
               -  CNS tumor(s) is clinically stable at the time of enrollment&#xD;
&#xD;
               -  Patient does not require corticosteroid or antiepileptic therapy for management&#xD;
                  of CNS metastases&#xD;
&#xD;
          -  Known hypersensitivity to any component of study treatment or excipients.&#xD;
&#xD;
          -  Positive antibody screen using institution's standard type and screen test.&#xD;
&#xD;
          -  Clinically significant, active and uncontrolled infection, including human&#xD;
             immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christina Coughlin, M.D., Ph.D.</last_name>
    <phone>617-679-9600</phone>
    <email>chris.coughlin@rubiustx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>SMukarram@theangelesclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Univeristy of Colorado Cancer Center Research Site</last_name>
      <email>POEMSintake@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ley</last_name>
      <phone>314-747-8092</phone>
      <email>jcley@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura &amp; Isaac Perlmutter Cancer Center at NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NYU Clinic Team</last_name>
      <email>PCC-Phase1@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OU Health Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silas Day</last_name>
      <phone>405-271-8001</phone>
      <email>Silas-Day@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natisha Muhammad</last_name>
      <email>Natisha.Muhammad@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brodeur</last_name>
      <phone>412-623-2944</phone>
      <email>brodeurs@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>615-329-7478</phone>
      <email>CANN.ResearchReferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Friedman</last_name>
      <phone>703-280-5390</phone>
      <email>Carrie.Friedman@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

